Prarthana Khanna

Leiden, Netherlands

• Partner with the CEO and Board on enterprise strategy, portfolio positioning, and capital allocation across RNA therapeutics programs.
• Lead licensing, M&A, strategic alliances, and external innovation initiatives to maximize pipeline and enterprise value.
• Structure, negotiate, and execute complex biotech transactions, leading cross-functional diligence and valuation activities.
• Advise leadership on financing strategy, strategic partnerships, and risk-adjusted portfolio prioritization.
• Lead investor engagement and external stakeholder strategy with current and prospective investors and partners.
• Build and scale business development and alliance management capabilities across Legal, Finance, and R&D.

Boston, MA

• Led strategic transactions including M&A, licensing, collaborations, and equity investments across obesity, cardiometabolic disease, oncology, AI-enabled drug discovery, and genetic medicine.
• Directed scientific, strategic, and commercial diligence for advanced therapeutic modalities and emerging technology platforms.
• Evaluated strategic fit, scalability, and risk-adjusted value across acquisition, licensing, and investment opportunities.
• Advised senior leadership on external innovation strategy and long-term R&D value creation.
• Influenced executive stakeholders and external partners on decisions involving novel technologies and innovation sourcing.
• Managed large-scale cross-functional initiatives involving significant financial and operational complexity.

Boston, MA

• Led partnership strategy supporting development of precision genetic medicines for sensorineural hearing loss.
• Built business development processes and cross-functional collaboration frameworks to advance strategic partnerships.
• Negotiated the $487M acquisition of Akouos by Eli Lilly, including contingent value rights up to approximately $610M.
• Developed transaction rationale, financial models, diligence strategy, and Board materials; supported HSR and SEC filings.
• Partnered directly with executives, bankers, investors, and external advisors throughout transaction execution.

Boston, MA

• Established and led North American and European out-licensing strategy for proprietary antibody and biologics platforms.
• Evaluated strategic growth opportunities in partnership with executive leadership.
• Negotiated and executed licensing agreements across oncology and immunology programs.
• Led multiple transactions involving platform technologies, strategic partnerships, and commercial licensing.

Cambridge, MA

• Managed a portfolio of 100+ therapeutic and diagnostic technologies across life sciences and physical sciences.
• Negotiated licenses, options, sponsored research agreements, and strategic collaborations.
• Advised faculty, founders, and postdoctoral fellows on commercialization strategy, startup formation, and industry partnerships.
• Supported institutional alliance management and translational innovation initiatives.

Charlestown, MA

• Conducted translational research focused on Huntington's disease therapeutics and biomarker discovery in collaboration with Novartis.
• Investigated genetic biomarkers and disease progression mechanisms supporting therapeutic development.